［1］ LHEUREUX S,BRAUNSTEIN M,OZA AM.Epithelial ovarian cancer:Evolution of management in the era of precision medicine ［J］.CA:A Cancer Journal for Clinicians,2019,69(4):280-304.
[2] ONEDA E,ZORZI F,GORIO A,et al.Differential diagnosis of small cell carcinoma of the ovary or ovarian metastases of small cell carcinoma of the lung:A case report and review of the literature ［J］.Case Reports in Oncology,2020,13(2):822-828.
[3] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
[4] CABASAG CJ,FAGAN PJ,FERLAY J,et al.Ovarian cancer today and tomorrow:A global assessment by world region and human development index using GLOBOCAN 2020 ［J］.International Journal of Cancer,2022,151(9):1535-1541.
[5] DAVIES M,DAVEY MG,MILLER N.The potential of microRNAs as clinical biomarkers to aid ovarian cancer diagnosis and treatment ［J］.Genes,2022,13(11):2054.
[6] ZHANG M,CHENG S,JIN Y,et al.Roles of CA125 in diagnosis,prediction,and oncogenesis of ovarian cancer ［J］.Biochimica et Biophysica Acta (BBA) - Reviews on Cancer,2021,1875(2):188503.
[7] MCCLUGGAGE WG,SINGH N,GILKS CB.Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020) ［J］.Histopathology,2022,80(5):762-778.
[8] WINER I,KIM C,GEHRIG P.Neuroendocrine tumors of the gynecologic tract update ［J］.Gynecol Oncol,2021,162(1):210-219.
[9] GEORGESCU TA,BOHILTEA RE,MUNTEANU O,et al.Emerging therapeutic concepts and latest diagnostic advancements regarding neuroendocrine tumors of the gynecologic tract ［J］.Medicina,2021,57(12):1338.
[10] EICHHORN JH,YOUNG RH,SCULLY RE.Primary ovarian small cell carcinoma of pulmonary type ［J］.The American Journal of Surgical Pathology,1992,16(10):926-927.
[11] MIGLIETTA S,GIROLIMETTI G,MARCHIO L,et al.MicroRNA and metabolic profiling of a primary ovarian neuroendocrine carcinoma pulmonary type reveals a high degree of similarity with small cell lung cancer ［J］.Non-coding RNA,2022,8(5):64-77.
[12] ZHAO FH,WANG JS,LIU HL,et al.Primary ovarian small cell carcinoma of pulmonary type:Analysis of 6 cases and review of 31 cases in the literatures ［J］.Chinese Medical Sciences Journal,2023,38(2):130-137.
[13] PARK HK.Neuroendocrine carcinomas of the uterine cervix,endometrium,and ovary show higher tendencies for bone,brain,and liver organotrophic metastases ［J］.Current Oncology,2022,29(10):7461-7469.
[14] BRENNAN SM,GREGORY DL,STILLIE A,et al.Should extrapulmonary small cell cancer be managed like small cell lung cancer［J］.Cancer,2010,116(4):888-895.
[15] JOSELUIS HR.Ovarian neuroendocrine carcinoma-case report ［J］.Obstetrics & Gynecology International Journal,2016,4(3):80-82.
[16] HAYASE T,MATSUBARA D,MAEDA K,et al.Pediatric ovarian dysgerminoma with highly elevated serum neuron-specific enolase ［J］.Pediatrics International,2018,60(10):982-983.
[17] TERADA S,SUZUKI T,HASEGAWA A,et al.The cytoreductive effect of radiotherapy for small cell ovarian carcinoma of the pulmonary type:A case report and review of the literature ［J］.Case Reports in Obstetrics and Gynecology,2018,2018(1):1-6.
[18] LENCHNER JR,SANTOS C.Biochemistry,5 hydroxyindoleacetic acid ［M］.Treasure Island(FL),StatPearls Publishing,2024:10-15.
[19] XING XY,ZHANG W,LIU LY,et al.Clinical analysis of 12 cases of ovarian neuroendocrine carcinoma ［J］.World Journal of Clinical Cases,2024,12(6):1111-1119.
[20] PANG L,GUO Z.Primary neuroendocrine tumors of the ovary:Management and outcomes ［J］.Cancer Medicine,2021,10(23):8558-8569.
[21] LI Y,WU Y,ZHANG Y,et al.Case report:Strategies for improving outcomes in patients with primary ovarian small-cell neuroendocrine carcinoma ［J］.Frontiers in Oncology,2022,12(16):954289.
[22] GUPTA P,KAPATIA G,GUPTA N,et al.Small cell carcinoma of the ovary:Clinicopathologic and immunohistochemical analysis of 7 new cases of a rare malignancy ［J］.Int J Surg Pathol,2021,29(3):236-245.
[23] ZHU Y,MENG F,FANG H,et al.Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary ［J］.Int J Gynecol Cancer,2020,30(2):207-212.
[24] CHAD R RUND,EDGAR G FISCHER.Perinuclear dot-like cytokeratin 20 staining in small cell neuroendocrine carcinoma of the ovary pulmonaary type［J］.Appl Immunohistochem Mol Morphol,2006,14(2):244-248.
[25] NASIOUDIS D,CHAPMAN-DAVIS E,FREY MK,et al.Small cell carcinoma of the ovary:A rare tumor with a poor prognosis ［J］.Int J Gynecol Cancer,2018,28(5):932-938.
[26] WANG J,NING Y,DU Y,et al.Lymphadenectomy benefits small cell carcinoma of ovary:A population-based analysis ［J］.Current Oncology,2022,29(10):7802-7815.
[27] YAGHMOUR G,PROUET P,WIEDOWER E,et al.Genomic alterations in neuroendocrine cancers of the ovary ［J］.Journal of Ovarian Research,2016,9(1):52-57.
[28] TISCHKOWITZ M,HUANG S,BANERJEE S,et al.Small-cell carcinoma of the ovary,hypercalcemic type-genetics,new treatment targets,and current management guidelines ［J］.Clinical Cancer Research,2020,26(15):3908-3917.
[29] MOSELE F,REMON J,MATEO J,et al.Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers:a report from the ESMO Precision Medicine Working Group ［J］.Annals of Oncology,2020,31(11):1491-1505.
[30] SU X,ZHOU X,XIAO C,et al.Complete response to immunotherapy combined with chemotherapy in a patient with gynecological mixed cancer mainly composed of small cell neuroendocrine carcinoma with high tumor mutational burden:A case report ［J］.Frontiers in Oncology,2022,12(16):750970.
[31] PANG L,WANG S.Prevalence,associated factors,and survival outcomes of small-cell neuroendocrine carcinoma of the gynecologic tract:A large population-based analysis ［J］.Frontiers in Medicine,2022,9(16):1-10.
[32] HU D,MA D,ZHANG ZJ,et al.Prognosis comparison between small cell carcinoma of ovary and high-grade serous ovarian cancer:A retrospective observational cohort study ［J］.Frontiers in Endocrinology,2023,18(14):1103429.